Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.

ABSTRACT:

Background

The humanized anti-CGRP monoclonal antibody eptinezumab has been evaluated in five large-scale clinical trials conducted in patients with migraine. This integrated analysis was conducted to evaluate the comprehensive safety and tolerability of eptinezumab in patients with migraine across these studies.

Methods

Data were pooled from four randomized, double-blind, placebo-controlled studies and the first year of one open-label study.

Results

The pooled population comprised 2867 adults with migraine: eptinezumab, n = 2076 (4797 infusions); placebo, n = 791 (1675 infusions). A total of 1137/2076 (54.8%) patients who received eptinezumab and 414/791 (52.3%) patients who received placebo experienced ≥1 treatment-emergent adverse event (TEAE); rates were similar a

SUBMITTER: Smith TR 

PROVIDER: S-EPMC8008612 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature